Dataset Information

A single, clinically relevant dose of the GABA_B agonist baclofen impairs visuomotor learning.

ABSTRACT:

Key points

Baclofen is a GABA_B agonist prescribed as a treatment for spasticity in stroke, brain injury and multiple sclerosis patients, who are often undergoing concurrent motor rehabilitation. Decreasing GABAergic inhibition is a key feature of motor learning and so there is a possibility that GABA agonist drugs, such as baclofen, could impair these processes, potentially impacting rehabilitation. Here, we examined the effect of 10 mg of baclofen, in 20 young healthy individuals, and found that the drug impaired retention of visuomotor learning with no significant effect on motor sequence learning. Overall baclofen did not alter transcranial magnetic stimulation-measured GABA_B inhibition, although the change in GABA_B inhibition correlated with aspects of visuomotor learning retention. Further work is needed to investigate whether taking baclofen impacts motor rehabilitation in patients.

Abstract

The GABA_B agonist baclofen is taken daily as a treatment for spasticity by millions of stroke, brain injury and multiple sclerosis patients, many of whom are also undergoing motor rehabilitation. However, decreases in GABA are suggested to be a key feature of human motor learning, which raises questions about whether drugs increasing GABAergic activity may impair motor learning and rehabilitation. In this double-blind, placebo-controlled study, we investigated whether a single 10 mg dose of the GABA_B agonist baclofen impaired motor sequence learning and visuomotor learning in 20 young healthy participants of both sexes. Participants trained on visuomotor and sequence learning tasks using their right hand. Transcranial magnetic stimulation (TMS) measures of corticospinal excitability, GABA_A (short-interval intracortical inhibition_, 2.5 ms) and GABA_B (long-interval intracortical inhibition_, 150 ms) receptor activation were recorded from left M1. Behaviourally, baclofen caused a significant reduction of visuomotor aftereffect (F_1,137.8 = 6.133, P = 0.014) and retention (F_1,130.7 = 4.138, P = 0.044), with no significant changes to sequence learning. There were no overall changes to TMS measured GABAergic inhibition with this low dose of baclofen. This result confirms the causal importance of GABA_B inhibition in mediating visuomotor learning and suggests that chronic baclofen use could negatively impact aspects of motor rehabilitation.

SUBMITTER: Johnstone A

PROVIDER: S-EPMC7611062 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Altered sensory information processing, and auditory processing, in particular, is a common impairment in individuals with autism spectrum disorder (ASD). One prominent hypothesis for the etiology of ASD is an imbalance between neuronal excitation and inhibition. The selective GABAB receptor agonist R-Baclofen has been shown previously to improve social deficits and repetitive behaviors in several mouse models for neurodevelopmental disorders including ASD, and its formulation Arbaclofen has been shown to ameliorate social avoidance symptoms in some individuals with ASD. The present study investigated whether R-Baclofen can remediate ASD-related altered sensory processing reliant on excitation/inhibition imbalance in the auditory brainstem. To assess a possible excitation/inhibition imbalance in the startle-mediating brainstem underlying ASD-like auditory-evoked behaviors, we detected and quantified brain amino acid levels in the nucleus reticularis pontis caudalis (PnC) of rats with a homozygous loss-of-function mutation in the ASD-linked gene Contactin-associated protein-like 2 (Cntnap2) and their wildtype (WT) littermates using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS). Abnormal behavioral read-outs of brainstem auditory signaling in Cntnap2 KO rats were accompanied by increased levels of GABA, glutamate, and glutamine in the PnC. We then compared the effect of R-Baclofen on behavioral read-outs of brainstem auditory signaling in Cntnap2 KO and WT rats. Auditory reactivity, sensory filtering, and sensorimotor gating were tested in form of acoustic startle response input-output functions, short-term habituation, and prepulse inhibition before and after acute administration of R-Baclofen (0.75, 1.5, and 3 mg/kg). Systemic R-Baclofen treatment improved disruptions in sensory filtering in Cntnap2 KO rats and suppressed exaggerated auditory startle responses, in particular to moderately loud sounds. Lower ASR thresholds in Cntnap2 KO rats were increased in a dose-dependent fashion, with the two higher doses bringing thresholds close to controls, whereas shorter ASR peak latencies at the threshold were further exacerbated. Impaired prepulse inhibition increased across various acoustic prepulse conditions after administration of R-Baclofen in Cntnap2 KO rats, whereas R-Baclofen did not affect prepulse inhibition in WT rats. Our findings suggest that GABAB receptor agonists may be useful for pharmacologically targeting multiple aspects of sensory processing disruptions involving neuronal excitation/inhibition imbalances in ASD.

Project description:As flattening filter-free (FFF) photon beams become readily available for treat-ment delivery in techniques such as SBRT, thorough investigation of skin dose from FFF photon beams is necessary under clinically relevant conditions. Using a parallel-plate PTW Markus chamber placed in a custom water-equivalent phantom, surface-dose measurements were taken at 2 × 2, 3 × 3, 4 × 4, 6 × 6, 8 × 8, 10 × 10, 20 × 20, and 30 × 30 cm2 field sizes, at 80, 90, and 100 cm source-to-surface distances (SSDs), and with fields defined by jaws and multileaf collimator (MLC) using multiple beam energies (6X, 6XFFF, 10X, and 10XFFF). The same set of measurements was repeated with the chamber at a reference depth of 10cm. Each surface measurement was normalized by its corresponding reference depth measurement for analysis. The FFF surface doses at 100 cm SSD were higher than flattened surface doses by 45% at 2 × 2 cm2 to 13% at 20 × 20 cm2 for 6MV energy. These surface dose differences varied to a greater degree as energy increased, ranging from +63% at 2 × 2 cm2 to -2% at 20 × 20 cm2 for 10 MV. At small field sizes, higher energy increased FFF surface dose relative to flattened surface dose; while at larger field sizes, relative FFF surface dose was higher for lower energies. At both energies investigated, decreasing SSD caused a decrease in the ratios of FFF-to-flattened surface dose. Variability with SSD of FFF-to-flattened surface dose differences increased with field size and ranged from 0% to 6%. The field size at which FFF and flattened beams gave the same skin dose increased with decreasing beam energy. Surface dose was higher with MLC fields compared to jaw fields under most conditions, with the difference reaching its maximum at a field size between 4 × 4 cm2 and 6 × 6 cm2 for a given energy and SSD. This study conveyed the magnitude of surface dose in a clinically meaning-ful manner by reporting results normalized to 10 cm depth dose instead of depth of dose maximum.

Project description:Background and aimsMicroRNAs (miRNAs) have been shown to play important roles in many cancers, including breast cancer. The majority of previous studies employed network analysis to identify key miRNAs in cancer progression. However, most of dysregulated miRNA networks were constructed based on the expression variation of miRNAs and target genes.MethodsThe relations between miRNAs and target genes were computed by Spearman correlation separately in breast cancer and normal breast samples. We calculated dysregulated scores based on the dysregulation of miRNA-mRNA regulatory relations. A dysregulated miRNA target network (DMTN) was constructed from the miRNA-mRNA pairs with significant dysregulated scores. SVM classifier was employed to predict breast cancer risk miRNAs from the DMTN. Hypermetric test was utilized to calculate the significance of overlap between different gene sets. Pearson correlation was used to evaluate associations between miRNAs/genes and drug response.ResultsThe DMTN comprised 511 miRNAs and was similar to common biological networks. Based on miRNAs and target genes in DMTN, we predicted 90 breast cancer risk miRNAs by using SVM classifier. Predicted risk miRNAs and one-step neighbor genes were significantly overlapping with differential miRNAs, cancer-related and housekeeping genes in breast cancer. These risk miRNAs were involved in many cancer-related and immune-related processes. In addition, most risk miRNAs were able to predict survival of breast cancer patients. More interestingly, some risk miRNAs and one-step neighbor genes were remarkably associated with immune cell infiltration. For example, high expression of hsa-miR-155 indicates high abundance of activated CD4+ T cells but low level of M2 macrophage infiltration. Furthermore, we identified 588 miRNA-drug and 3,146 gene-drug pairs, wherein the expression level of miRNAs/genes could indicate the sensitivity of cancer cells to anti-cancer drugs.ConclusionWe predicted 90 breast cancer risk miRNAs based on proposed DMTN by using SVM classifier. Predicted risk miRNAs are biologically and clinically relevant in breast cancer. Risk miRNAs and one-step neighbor genes could serve as biomarkers for immune cell infiltration and anti-cancer drug response, which sheds lights on immunotherapy or targeted therapy for patients with breast cancer.

Dataset Information

A single, clinically relevant dose of the GABA_B agonist baclofen impairs visuomotor learning.

Key points

Abstract

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

A single, clinically relevant dose of the GABAB agonist baclofen impairs visuomotor learning.

Key points

Abstract

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

A single, clinically relevant dose of the GABA_B agonist baclofen impairs visuomotor learning.